학술논문
India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care
Document Type
Article
Author
Veeraraghavan, Balaji; Bakthavatchalam, Yamuna Devi; Manesh, Abi; Lal, Binesh; Swaminathan, Subramanian; Ansari, Abdul; Subbareddy, K.; Rangappa, Pradeep; Choudhuri, Anirban Hom; Nagvekar, Vasant; Mehta, Yatin; Appalaraju, Boppe; Baveja, Sujata; Baliga, Shrikala; Shenoy, Suchitra; Bhardwaj, Renu; Kongre, Vaishali; Dattatraya, Gogi Suresh; Verma, Binita; Mukherjee, D.N.; Gupta, Shalini; Shanmugam, Priyadarshini; Iravane, Jyoti; Mishra, Sudhi Ranjan; Barman, Purabi; Chopra, Shimpi; Hariharan, Meenakshi; Surpam, Rajendra; Pratap, Rana; Turbadkar, Dilip; Taklikar, Shripad
Source
Indian Journal of Medical Microbiology; 20220101, Issue: Preprints
Subject
Language
ISSN
02550857
Abstract
Levonadifloxacin (intravenous) and alalevonadifloxacin (oral prodrug) are novel antibiotics based on benzoquinolizine subclass of fluoroquinolone, licensed for clinical use in India in 2019. The active moiety, levonadifloxacin, is a broad-spectrum antibiotic with a high potency against methicillin-resistant Staphylococcus. aureus, multi-drug resistant pneumococci and anaerobes.